Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ICPT closed up 3.14 percent on Tuesday, June 19, 2018, on 88 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Up||Up||Up|
|See historical ICPT trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 19||Upper Bollinger Band Walk||Strength||0.00%|
|Jun 19||Overbought Stochastic||Strength||0.00%|
|Jun 19||Upper Bollinger Band Touch||Strength||0.00%|
|Jun 18||NR7||Range Contraction||3.14%|
|Jun 18||Upper Bollinger Band Walk||Strength||3.14%|
|Jun 18||Inside Day||Range Contraction||3.14%|
|Jun 18||Overbought Stochastic||Strength||3.14%|
|Jun 15||Upper Bollinger Band Walk||Strength||2.28%|
|Jun 15||Above Upper BB||Strength||2.28%|
|Jun 15||Overbought Stochastic||Strength||2.28%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ICPT news...
|52 Week High||135.59|
|52 Week Low||51.05|
|200-Day Moving Average||67.3114|
|50-Day Moving Average||72.4604|
|20-Day Moving Average||75.395|
|10-Day Moving Average||79.134|
|Average True Range||3.5016|
|Chandelier Exit (Long, 3 ATRs )||75.2152|
|Chandelier Exit (Short, 3 ATRs )||76.1348|
|Upper Bollinger Band||85.2162|
|Lower Bollinger Band||65.5738|
|Percent B (%b)||0.98|
|MACD Signal Line||2.3723|
|Market Cap||2.13 Billion|
|Num Shares||25.1 Million|
|Price-to-Earnings (P/E) Ratio||-5.48|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||91.26|
|Resistance 3 (R3)||90.84||88.28||90.18|
|Resistance 2 (R2)||88.28||86.64||88.49||89.82|
|Resistance 1 (R1)||86.55||85.63||87.42||86.97||89.47|
|Support 1 (S1)||82.26||82.35||83.13||82.68||80.17|
|Support 2 (S2)||79.70||81.34||79.91||79.82|
|Support 3 (S3)||77.97||79.70||79.46|
|Support 4 (S4)||78.39|